NCT03877120View on ClinicalTrials.gov

Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán

PHASE4CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

February 28, 2018

Study Completion Date

August 31, 2018

Conditions
Alcohol Withdrawal Delirium
Interventions
DRUG

Dexmedetomidine 0.004 MG/ML

Experimental studies and single case reports suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol withdrawal.

DRUG

Diazepam Injectable Solution

diazepam start with 5-20 mg IV as a dose response, steps until a maximum dose of 120 mg diazepam.

Trial Locations (1)

4780000

Nayely Garcia Mendez, Mexico City

All Listed Sponsors
collaborator

Universidad de La Frontera

OTHER

lead

Centro Medico Nacional La Raza, IMSS

OTHER

NCT03877120 - Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán | Biotech Hunter | Biotech Hunter